Since 1980, the term "undifferentiated connective tissue disease" (UCTD) has been used (1) to define conditions characterized by the presence of signs and symptoms of a systemic autoimmune disease that does not fulfil the classification criteria for a defined disease (2) (3) (4) (5) (6) (7) . These conditions have also been named by many authors as "latent lupus" (8) , "incomplete lupus erythematosus" (9) or "early undifferentiated connective tissue disease" (10) .
There is a female predominance in UCTD patients similar to that observed in common connective tissue diseases. The onset of UCTD is similar to most connective tissue diseases, peaking in the middle years of life (11) (12) (13) (14) . The etio-pathogenesis is unknown and prognosis is better than that observed in other differentiated connective tissue diseases. Patients may present many different systemic symptoms but visceral involvement is rare (15) (16) (17) . The antinuclear antibody (ANA) title is generally high (11) (12) (13) (14) (15) (16) (17) (18) however it is not always considered as a diagnostic marker of the disease.
After onset, UCTD may remain indefinite over a period of years. This is described in about 70% of the reported cases in literature. It may show a spontaneous, or drug-induced, clinical regression or, on the other hand, a progressive evolution to a defined connective tissue disease (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) may be seen mainly represented by systemic lupus erythematosus (SLE) (12, 14-16, 19,24) .
We describe here the clinical and serological aspects of this syndrome in a cohort of patients initially diagnosed as having early UCTD. We have also assessed the clinical evolution of the disease over time in this group of subjects, partially by reviewing available medical records and also by a prospective follow-up observation. All the patients included in the study underwent clinical monitoring, and treatment was only used in symptomatic subjects.
MATERIALS AND METHODS
Between 1995 and 2006, we studied 45 patients, aged between 14 and 73 years (5 males and 40 females), with a diagnosis of early UCTD made at the Department of Clinical Medicine, Sapienza University of Rome. The subjects enrolled underwent laboratory tests and medical examinations on an out patient schedule.
All these subjects presented signs and symptoms suggestive of connective tissue disease but did not fulfil the classification criteria for a defined disease. We excluded patients with a CTD diagnosis such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic sclerosis (SSe), polydermatomyositis (PM/DM) and mixed connective tissue disease (MCTD).
Patients were selected according to the following criteria:
1. Diagnosis of early UCTD 2. Medical records of clinical symptoms lasting at least 1 year.
Epidemiological, clinical, serological and instrumental data were collected from each patient at the time of diagnosis and during a 3 year follow-up.
The initial diagnosis was re-evaluated at each follow-up visit with a complete medical history, physical examination and laboratory tests. Patients previously treated with hydroxychloroquine, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, immunosuppressant agents (cyclosporine, azathioprine and methotrexate) and calcium channel blockers, were also included.
Standard and validated techniques were used for laboratory tests.
The indirect immunofluorescence (IIF) technique was used on Hep-2 cells and Crithidia luciliae, respectively for the determination of antinuclear antibodies (ANA) and anti-ds-DNA antibodies, whereas anti-extractable nuclear antigen antibodies (anti-ENA: anti-SSA/Ro, anti-SSB/La, anti-RNP, anti-Sm, anti-Scl 70, anti-Jo l) were determined with counter immune-electrophoresis. Anti-neutrophil cytoplasmic antibodies (ANCA), smooth muscle antibodies (SMA), antimitochondrial antibodies (AMA) and antibodies to liver kidney microsomal antigen type-l (anti-LKMl) were documented by indirect immunofluorescence assay, while Rheumatoid Factor (RF) by agglutination tests. Anticardiolipin antibodies (ACA) and anti-cyclic citrullinated peptide antibodies (anti-CCP IgG) were detected using an enzyme-linked immunosorbent assay (ELISA). The determination of Lupus anti-coaugulant (LAC) was made by screening assays included kaolin clotting time, dilute APTT, dilute PT, and 2 dilute Russell viper venom times. Thrombocytopenia was studied by Dixon's assay, measuring platelet-associated IgG by a complement lysis-inhibition technique.
Patients were also checked for hepatitis Band C viruses serology.
Statistical analysis
Data not paired were compared with Mann-Whitney U-test; a P value <0.05 was considered statistically significant.
RESULTS
Forty-one of the 45 initially observed patients affected by early UCTD were enrolled in this study; 36 were female and 5 male, with an average age of 43.5 years (range 14-73 years). They all presented at least one year of medical history referring to early UCTD. The remaining 4 subjects were excluded from the analysis because their symptoms were more recent than one year.
The most common clinical manifestations present at diagnosis in our patients are described in Table I . The majority ofpatients had more than 3 or 4 clinical simultaneous manifestations, but a few presented serious organ involvement. However, 12% of the subjects had cardiovascular diseases with particular involvement of the pericardium (four episodes of pericarditis), three patients had positive histories for arterial and venous occlusions, with 2 cerebral vascular occurences and only three patients had lung involvement, predominantly pleuritis. At the time of diagnosis, positivity of ANA ( Fig. I) was the most frequent immunological abnormality observed. Other immunological parameters not shown in Fig.l , as AMA, ANCA, anti-CCP and anti-LKM-1, were never present at diagnosis while Dixon's assay was positive in two of the three patients with thrombocytopenia. All subjects resulted negative for hepatitis viruses serology. At the time of enrolment in the study, the majority of the subjects had begun treatment with an association of one or more drugs including: 1. NSAIDs 2. Corticosteroids 3. Hydroxychloroquine 4. Immunosuppressant agents (cyclosporine, azathioprine and methotrexate) 5. Calcium channel blockers (only in patients with vasculitis or Raynaud's phenomenon) 6. Antiplatelet drugs in subjects with APS or Raynaud's phenomenon. An association of more drugs was necessary in 60% of the patients, but only 15% were treated with immunosuppressant agents after the failure of NSAIDs therapy.
The clinical condition of each patient was assessed at every year of follow-up.
As reported in literature (12) , clinical manifestations remained largely unchanged in our cohort of patients after one year from diagnosing early UCTD (Fig. 2) . A significant regression (P = 0.01) was only found in erythema nodosum, whereas the other signs and symptoms did not show any significant changes during the follow-up.
Other clinical manifestations such as Raynaud's phenomenon, vasculitis, peripheral neuropathy and uveitis, did not show significant changes over time. Similarly, the serological profiles did not undergo significant modifications in the first year of followup, and immunological parameters, such as ANA, Rheumatoid factor, anti-ENA and anti-ds DNA, remained unchanged over time (Fig. 3) .
Even the inflammation indices (ESR and CRP) remained largely unmodified although they were altered in fewer subjects than at diagnosis.
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Regression 27% UCTD 52% Fig. 4 . Clinical evolution ofthe 29 patients with early UCrD diagnosis that reached the third year offollow-up. More than halfof these patients (52%) maintained an undifferentiated profile during the study, 27% showed a clinical regression and 21% evolved to a differentiated connective tissue disease.
a regression of clinical symptoms. No changes were observed in the other laboratory parameters evaluated over the period of time. Even checks in the second and third years of follow-up showed little changes in the reported frequencies of arthralgia, poliarthritis, fever and muscle aches. The other clinical manifestations, as Raynaud's phenomenon and Sicca Syndrome remained unchanged (Fig. 2) .
During the 3 years of follow-up carried out on the 41 patients included in the study, 6 of them (15%) evolved to a differentiated connective tissue disease, 15 (37%) maintained an undifferentiated profile, 8 (19%) showed clinical regression and 12 (29%) were lost during follow-up. The frequency of clinical evolution was only considered in the 29 patients completing the 3-year follow-up and was modified as follows: 52% remained with a diagnosis of UCTD, 27% showed clinical regression whereas 21% developed CTD (Fig. 4) .
According to the international criteria of classification of CTD (2-7), of the 6 patients who clinically evolved to defined CTD, 2 developed SLE, and the other 4 developed as follows: one MCTD, one APS, one RA and one Autoimmune Chronic Hepatitis (with AMA positivity). This last diagnosis was also confirmed by liver biopsy.
DISCUSSION
In recent years many theories have been proposed regarding those autoimmune diseases defined as "incomplete", that present typical features of connective tissue diseases while not fulfilling the classification criteria for defined CTD. These diseases have been indicated in different ways, such as "latent lupus" (8) or "incomplete lupus" (9) , in order to underline the correlation with SLE, while early UCTD (10) is another definition indicating the evolutionary nature of the disease. At present UCTD is defined as an autoimmune disorder characterized by ANA positivity, signs and symptoms suggestive of a CTD that persist for at least three years and not meeting the classification criteria for specific CTD (15) (16) . According to international literature, in our cohort we found that UCTD is most frequent in females (M:F ratio I :6), aging from 40 to 50 years. Generally, our patients presented 3 or 4 clinical manifestations simultaneously, but only a few ofthem showed visceral involvement. Despite this, we were able to demonstrate a low rate of cardiac diseases, particularly of the pericardium. Therefore, it is important to perform an echocardiogram regularly at the time of diagnosis and during follow-up, in order to exclude immediately the presence of pericarditis or polysierositis. As in other CTDs, UCTD may present some associations with other autoimmune disorders, particularly with autoimmune thyroiditis.
The appearance of clinical manifestations usually remains stable during time with the exception of polyarthritis, fever, and eritema nodosum, more responsive to treatment than other symptoms. No correlation was found between the increased values of ANA, RF or other autoantibodies and a more aggressive clinical course. Therefore, we hypothesize that the autoantibody panel does not represent an unfavourable prognostic factor for evolution to CTD, whereas the appearance of a new sign/symptom or a new autoantibody during the first years of follow-up seems to be a negative prognostic factor for clinical evolution to defined CTD. In agreement with these observations, UCTD is a particular clinical entity that needs strict monitoring at least every 6 months together with accurate clinical, serological and instrumental evaluations to be performed before starting therapy and during follow-up.
It is also important to strictly monitor those patients that present clinical regression. In fact, it cannot be definitively excluded that some of these subjects could suffer a recurrence ofthe autoimmune disease again even after the three years of followup.
To date, there is no specific therapy for UCTD, whereas special therapies are generally employed for the reported manifestations of the disease. In our experience, the use of a non-aggressive therapy based on hydrossicloroquine, NSAIDs and low doses of corticosteroids are generally efficient in maintaining the disease in an inactive status.
Due to the evolution of early UCTD to specific CTD, as observed in 21% of our treated patients, we cannot state that a moderately aggressive therapy could represent a barrier to the evolution of the disease. However, the positive results in the control of arthralgias, functional limitations, myalgias and fever obtained with the treatment in many patients clearly indicate the utility of this approach.
The limitation of this study is that it is observational, not blinded or placebo-controlled, so clearly it cannot be excluded that the regression of the clinical manifestations observed after treatment would also be regressed even in the absence of therapy. The question of the efficacy of treatment in UCTD may only be answered by a multicentric randomized study versus placebo. Only this kind of study could fully indicate whether the treatment is able or not to modify the clinical course of UCTD during time.
